Acumen Pharmaceuticals, Inc. Operating Expenses
Acumen Pharmaceuticals, Inc. (ABOS) reported Operating Expenses of $32.56 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-12
- Acumen Pharmaceuticals, Inc. operating expenses for the quarter ending 2026-06-30 was $32.56M, a 22.02% decline year-over-year.
- Acumen Pharmaceuticals, Inc. operating expenses for the quarter ending 2026-03-31 was $21.15M, a 30.36% decline year-over-year.
- Acumen Pharmaceuticals, Inc. operating expenses for the quarter ending 2025-12-31 was $25.20M, a 36.36% decline year-over-year.
- Acumen Pharmaceuticals, Inc. operating expenses for the quarter ending 2025-09-30 was $26.51M, a 17.83% decline year-over-year.
- Acumen Pharmaceuticals, Inc. operating expenses for fiscal 2025 was $123.83M, a 8.61% increase from fiscal 2024.
- Acumen Pharmaceuticals, Inc. operating expenses for fiscal 2024 was $114.02M, a 86.49% increase from fiscal 2023.
- Acumen Pharmaceuticals, Inc. operating expenses for fiscal 2023 was $61.14M, a 35.15% increase from fiscal 2022.
- Acumen Pharmaceuticals, Inc. operating expenses for fiscal 2022 was $45.24M, a 130.99% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $32.56M 10-Q · filed 2026-08-12 | $53.70M 10-Q · filed 2026-08-12 | $78.90M derived: sum of 3 quarters · filed 2026-08-12 | $105.42M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $21.15M 10-Q · filed 2026-05-12 | $46.35M derived: sum of 2 quarters · filed 2026-05-12 | $72.86M derived: sum of 3 quarters · filed 2026-05-12 | $114.61M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $25.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $51.71M derived: sum of 2 quarters · filed 2026-03-26 | $93.46M derived: sum of 3 quarters · filed 2026-08-12 | $123.83M 10-K · filed 2026-03-26 |
| 2025-09-30 | $26.51M 10-Q · filed 2025-11-12 | $68.26M derived: sum of 2 quarters · filed 2026-08-12 | $98.63M 10-Q · filed 2025-11-12 | $138.23M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $41.75M 10-Q · filed 2026-08-12 | $72.12M 10-Q · filed 2026-08-12 | $111.72M derived: sum of 3 quarters · filed 2026-08-12 | $143.98M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $30.37M 10-Q · filed 2026-05-12 | $69.97M derived: sum of 2 quarters · filed 2026-05-12 | $102.23M derived: sum of 3 quarters · filed 2026-05-12 | $126.61M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $39.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $71.86M derived: sum of 2 quarters · filed 2026-03-26 | $96.24M derived: sum of 3 quarters · filed 2026-03-26 | $114.02M 10-K · filed 2026-03-26 |
| 2024-09-30 | $32.27M 10-Q · filed 2025-11-12 | $56.65M derived: sum of 2 quarters · filed 2025-11-12 | $74.42M 10-Q · filed 2025-11-12 | $92.91M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $24.38M 10-Q · filed 2025-08-12 | $42.16M 10-Q · filed 2025-08-12 | $60.64M derived: sum of 3 quarters · filed 2025-08-12 | $76.68M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $17.77M 10-Q · filed 2025-05-13 | $36.26M derived: sum of 2 quarters · filed 2025-05-13 | $52.30M derived: sum of 3 quarters · filed 2025-05-13 | $65.78M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $18.49M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $34.52M derived: sum of 2 quarters · filed 2025-03-27 | $48.00M derived: sum of 3 quarters · filed 2025-03-27 | $61.14M 10-K · filed 2025-03-27 |
| 2023-09-30 | $16.04M 10-Q · filed 2024-11-12 | $29.52M derived: sum of 2 quarters · filed 2024-11-12 | $42.65M 10-Q · filed 2024-11-12 | $56.90M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $13.48M 10-Q · filed 2024-08-13 | $26.61M 10-Q · filed 2024-08-13 | $40.86M derived: sum of 3 quarters · filed 2024-08-13 | $52.23M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $13.13M 10-Q · filed 2024-05-14 | $27.38M derived: sum of 2 quarters · filed 2024-05-14 | $38.75M derived: sum of 3 quarters · filed 2024-05-14 | $49.16M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $14.25M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $25.62M derived: sum of 2 quarters · filed 2024-03-26 | $36.03M derived: sum of 3 quarters · filed 2024-03-26 | $45.24M 10-K · filed 2024-03-26 |
| 2022-09-30 | $11.37M 10-Q · filed 2023-11-13 | $21.78M derived: sum of 2 quarters · filed 2023-11-13 | $30.99M 10-Q · filed 2023-11-13 | $39.40M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $10.41M 10-Q · filed 2023-08-08 | $19.62M 10-Q · filed 2023-08-08 | $28.03M derived: sum of 3 quarters · filed 2023-08-08 | $31.97M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $9.21M 10-Q · filed 2023-05-09 | $17.62M derived: sum of 2 quarters · filed 2023-05-09 | $21.56M derived: sum of 3 quarters · filed 2023-05-09 | $25.00M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $8.41M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $12.35M derived: sum of 2 quarters · filed 2023-03-27 | $15.79M derived: sum of 3 quarters · filed 2023-03-27 | $19.58M 10-K · filed 2023-03-27 |
| 2021-09-30 | $3.94M 10-Q · filed 2022-11-14 | $7.38M derived: sum of 2 quarters · filed 2022-11-14 | $11.17M 10-Q · filed 2022-11-14 | $12.84M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $3.44M 10-Q · filed 2022-08-15 | $7.23M 10-Q · filed 2022-08-15 | $8.90M derived: sum of 3 quarters · filed 2022-08-15 | $12.12M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $3.79M 10-Q · filed 2022-05-16 | $5.46M derived: sum of 2 quarters · filed 2022-05-16 | $8.68M derived: sum of 3 quarters · filed 2022-05-16 | $10.87M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $1.67M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $4.89M derived: sum of 2 quarters · filed 2022-03-28 | $7.08M derived: sum of 3 quarters · filed 2022-03-28 | $9.35M 10-K · filed 2022-03-28 |
| 2020-09-30 | $3.22M 10-Q · filed 2021-11-15 | $5.41M derived: sum of 2 quarters · filed 2021-11-15 | $7.68M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $2.19M 10-Q · filed 2021-08-16 | $4.46M 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |